10 patients, but one dropped out, so 9. 6 were given a negligible dose for safety and one of these later died. One of the three remaining lied about heart issue

10 patients, but one dropped out, so 9. 6 were given a negligible dose for safety and one of these later died. One of the three remaining lied about heart issues and had a serious heart attack immediately after injection. So at best you have a sample size of two. Two people!! Really not the promising study the title suggests. "They plan to enroll ~40 more patients. Meanwhile a new version of the therapy, VERVE-102, is in the works. The newcomer uses a similar base editing technology and an upgraded nanoparticle carrier with potentially better targeting. The team plans to launch a randomized, placebo-controlled trial by 2025" So that might be promising, albeit later.